Literature DB >> 27497298

Loss of FBXO7 (PARK15) results in reduced proteasome activity and models a parkinsonism-like phenotype in mice.

Siv Vingill1, David Brockelt1, Camille Lancelin2, Lars Tatenhorst3, Guergana Dontcheva4, Christian Preisinger5, Nicola Schwedhelm-Domeyer6, Sabitha Joseph4, Miso Mitkovski7, Sandra Goebbels8, Klaus-Armin Nave9, Jörg B Schulz10, Till Marquardt11, Paul Lingor3, Judith Stegmüller12.   

Abstract

Mutations in the FBXO7 (PARK15) gene have been implicated in a juvenile form of parkinsonism termed parkinsonian pyramidal syndrome (PPS), characterized by Parkinsonian symptoms and pyramidal tract signs. FBXO7 (F-box protein only 7) is a subunit of the SCF (SKP1/cullin-1/F-box protein) E3 ubiquitin ligase complex, but its relevance and function in neurons remain to be elucidated. Here, we report that the E3 ligase FBXO7-SCF binds to and ubiquitinates the proteasomal subunit PSMA2. In addition, we show that FBXO7 is a proteasome-associated protein involved in proteasome assembly. In FBXO7 knockout mice, we find reduced proteasome activity and early-onset motor deficits together with premature death. In addition, we demonstrate that NEX (neuronal helix-loop-helix protein-1)-Cre-induced deletion of the FBXO7 gene in forebrain neurons or the loss of FBXO7 in tyrosine hydroxylase (TH)-positive neurons results in motor defects, reminiscent of the phenotype in PARK15 patients. Taken together, our study establishes a vital role for FBXO7 in neurons, which is required for proper motor control and accentuates the importance of FBXO7 in proteasome function.
© 2016 The Authors.

Entities:  

Keywords:  FBXO7; PARK15; PSMA2; parkinsonism; ubiquitination

Mesh:

Substances:

Year:  2016        PMID: 27497298      PMCID: PMC5282834          DOI: 10.15252/embj.201593585

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  65 in total

1.  PI31 is a modulator of proteasome formation and antigen processing.

Authors:  Dietmar M W Zaiss; Sybille Standera; Peter-M Kloetzel; Alice J A M Sijts
Journal:  Proc Natl Acad Sci U S A       Date:  2002-10-08       Impact factor: 11.205

2.  Intranigral infusion of interleukin-1beta activates astrocytes and protects from subsequent 6-hydroxydopamine neurotoxicity.

Authors:  Josep Saura; Mireia Parés; Jordi Bové; Susana Pezzi; Jordi Alberch; Concepció Marin; Eduardo Tolosa; María José Martí
Journal:  J Neurochem       Date:  2003-05       Impact factor: 5.372

3.  Skp2-dependent ubiquitination and activation of LKB1 is essential for cancer cell survival under energy stress.

Authors:  Szu-Wei Lee; Chien-Feng Li; Guoxiang Jin; Zhen Cai; Fei Han; Chia-Hsin Chan; Wei-Lei Yang; Bin-Kui Li; Abdol Hossein Rezaeian; Hong-Yu Li; Hsuan-Ying Huang; Hui-Kuan Lin
Journal:  Mol Cell       Date:  2015-02-26       Impact factor: 17.970

4.  Transforming activity of Fbxo7 is mediated specifically through regulation of cyclin D/cdk6.

Authors:  Heike Laman; Juan M Funes; Hongtao Ye; Stephen Henderson; Laura Galinanes-Garcia; Eiji Hara; Phillip Knowles; Neil McDonald; Chris Boshoff
Journal:  EMBO J       Date:  2005-08-11       Impact factor: 11.598

5.  Hypersensitivity of DJ-1-deficient mice to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyrindine (MPTP) and oxidative stress.

Authors:  Raymond H Kim; Patrice D Smith; Hossein Aleyasin; Shawn Hayley; Matthew P Mount; Scott Pownall; Andrew Wakeham; Annick J You-Ten; Suneil K Kalia; Patrick Horne; David Westaway; Andres M Lozano; Hymie Anisman; David S Park; Tak W Mak
Journal:  Proc Natl Acad Sci U S A       Date:  2005-03-22       Impact factor: 11.205

6.  Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.

Authors:  Ning Zheng; Brenda A Schulman; Langzhou Song; Julie J Miller; Philip D Jeffrey; Ping Wang; Claire Chu; Deanna M Koepp; Stephen J Elledge; Michele Pagano; Ronald C Conaway; Joan W Conaway; J Wade Harper; Nikola P Pavletich
Journal:  Nature       Date:  2002-04-18       Impact factor: 49.962

7.  Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress.

Authors:  Clement A Gautier; Tohru Kitada; Jie Shen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-08-07       Impact factor: 11.205

8.  Ubiquitin is a common factor in intermediate filament inclusion bodies of diverse type in man, including those of Parkinson's disease, Pick's disease, and Alzheimer's disease, as well as Rosenthal fibres in cerebellar astrocytomas, cytoplasmic bodies in muscle, and mallory bodies in alcoholic liver disease.

Authors:  J Lowe; A Blanchard; K Morrell; G Lennox; L Reynolds; M Billett; M Landon; R J Mayer
Journal:  J Pathol       Date:  1988-05       Impact factor: 7.996

9.  Protection of dopaminergic neurons with a novel astrocyte modulating agent (R)-(-)-2-propyloctanoic acid (ONO-2506) in an MPTP-mouse model of Parkinson's disease.

Authors:  Hiroyuki Kato; Tsutomu Araki; Yutaka Imai; Akira Takahashi; Yasuto Itoyama
Journal:  J Neurol Sci       Date:  2003-04-15       Impact factor: 3.181

10.  Loss of nuclear activity of the FBXO7 protein in patients with parkinsonian-pyramidal syndrome (PARK15).

Authors:  Tianna Zhao; Esther De Graaff; Guido J Breedveld; Agnese Loda; Lies-Anne Severijnen; Cokkie H Wouters; Frans W Verheijen; Marieke C J Dekker; Pasquale Montagna; Rob Willemsen; Ben A Oostra; Vincenzo Bonifati
Journal:  PLoS One       Date:  2011-02-11       Impact factor: 3.240

View more
  18 in total

1.  PI31 Is an Adaptor Protein for Proteasome Transport in Axons and Required for Synaptic Development.

Authors:  Kai Liu; Sandra Jones; Adi Minis; Jose Rodriguez; Henrik Molina; Hermann Steller
Journal:  Dev Cell       Date:  2019-07-18       Impact factor: 12.270

2.  Myelinating Glia-Specific Deletion of Fbxo7 in Mice Triggers Axonal Degeneration in the Central Nervous System Together with Peripheral Neuropathy.

Authors:  Sabitha Joseph; Siv Vingill; Olaf Jahn; Robert Fledrich; Hauke B Werner; Istvan Katona; Wiebke Möbius; Mišo Mitkovski; Yuhao Huang; Joachim Weis; Michael W Sereda; Jörg B Schulz; Klaus-Armin Nave; Judith Stegmüller
Journal:  J Neurosci       Date:  2019-05-13       Impact factor: 6.167

3.  Impaired mitochondrial accumulation and Lewy pathology in neuron-specific FBXO7-deficient mice.

Authors:  Sachiko Noda; Shigeto Sato; Takahiro Fukuda; Shinichi Ueno; Norihiro Tada; Nobutaka Hattori
Journal:  Mol Brain       Date:  2022-06-14       Impact factor: 4.399

Review 4.  The Emerging Roles of E3 Ligases and DUBs in Neurodegenerative Diseases.

Authors:  Na Liu; Miao-Miao Lin; Yan Wang
Journal:  Mol Neurobiol       Date:  2022-10-19       Impact factor: 5.682

Review 5.  Are we listening to everything the PARK genes are telling us?

Authors:  Deanna L Benson; George W Huntley
Journal:  J Comp Neurol       Date:  2019-02-08       Impact factor: 3.215

6.  The proteasome regulator PI31 is required for protein homeostasis, synapse maintenance, and neuronal survival in mice.

Authors:  Adi Minis; Jose A Rodriguez; Avi Levin; Kai Liu; Eve-Ellen Govek; Mary E Hatten; Hermann Steller
Journal:  Proc Natl Acad Sci U S A       Date:  2019-11-21       Impact factor: 11.205

Review 7.  Ubiquitin and Parkinson's disease through the looking glass of genetics.

Authors:  Helen Walden; Miratul M K Muqit
Journal:  Biochem J       Date:  2017-04-13       Impact factor: 3.857

Review 8.  Parkinson Disease from Mendelian Forms to Genetic Susceptibility: New Molecular Insights into the Neurodegeneration Process.

Authors:  Amin Karimi-Moghadam; Saeid Charsouei; Benjamin Bell; Mohammad Reza Jabalameli
Journal:  Cell Mol Neurobiol       Date:  2018-04-26       Impact factor: 5.046

9.  Low-Expressing Synucleinopathy Mouse Models Based on Oligomer-Forming Mutations and C-Terminal Truncation of α-Synuclein.

Authors:  Ana Martinez Hernandez; Ivan Silbern; Insa Geffers; Lars Tatenhorst; Stefan Becker; Henning Urlaub; Markus Zweckstetter; Christian Griesinger; Gregor Eichele
Journal:  Front Neurosci       Date:  2021-06-17       Impact factor: 4.677

10.  Impaired proteasome activity and neurodegeneration with brain iron accumulation in FBXO7 defect.

Authors:  Marta Correa-Vela; Vincenzo Lupo; Marta Montpeyó; Paula Sancho; Anna Marcé-Grau; Jorge Hernández-Vara; Alejandra Darling; Alison Jenkins; Sandra Fernández-Rodríguez; Cristina Tello; Laura Ramírez-Jiménez; Belén Pérez; Ángel Sánchez-Montáñez; Alfons Macaya; María J Sobrido; Marta Martinez-Vicente; Belén Pérez-Dueñas; Carmen Espinós
Journal:  Ann Clin Transl Neurol       Date:  2020-08-06       Impact factor: 4.511

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.